Literature DB >> 24215855

Recurrence of ovarian endometrioma after second-line, conservative, laparoscopic cyst enucleation.

Mi-La Kim1, Joo Myoung Kim2, Seok Ju Seong1, Soo Yoon Lee2, Myoungseok Han3, Yeon Jean Cho4.   

Abstract

OBJECTIVE: We sought to evaluate the cumulative recurrence rate of endometrioma after a second-line, conservative, laparoscopic endometriotic cyst enucleation and to analyze the factors that influence the recurrence of endometrioma. STUDY
DESIGN: A multicenter retrospective cohort study was performed at 3 gynecologic surgery centers from January 2000 through December 2010. Patients surgically treated by laparoscopic enucleation of endometriotic cysts on 2 previous occasions were selected. All patients were aged <40 years at the time of the primary surgery and were followed up for at least 6 months. Endometrioma recurrence was considered when transvaginal sonography indicated a cystic mass with a diameter of ≥20 mm.
RESULTS: In total, 183 patients were followed up for 33.2 ± 27.7 months (range, 6-121 months). Thirty-eight (20.8%) patients experienced recurrence after the second-line surgery and 24 (13.1%) patients underwent a third surgery. The median time to recurrence was 24 ± 3.36 months (SEM) (range, 3-72 months). The cumulative recurrence rates per patient at 12, 24, 36, and 60 months after the second-line surgery were 7.7%, 13.7%, 21.3%, and 37.5%, respectively. After multivariate analysis and analysis of covariance, the revised American Fertility Society score and stage were significantly higher in patients who experience a third recurrence of endometrioma.
CONCLUSION: The cumulative recurrence rate of ovarian endometrioma after a second-line surgery appears to be correlated to the duration of follow-up. Severe endometriosis at the second-line surgery seems to be a factor associated with a high recurrence risk. Physicians should be cautious with regard to the postoperative management of these patients.
Copyright © 2014 Mosby, Inc. All rights reserved.

Entities:  

Keywords:  conservative surgery; endometrioma; endometriosis; recurrence rate; second-line surgery

Mesh:

Year:  2013        PMID: 24215855     DOI: 10.1016/j.ajog.2013.11.007

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  6 in total

1.  Endometriosis: Survey of Current Diagnostic and Therapeutic Options and Latest Research Work.

Authors:  I Juhasz-Böss; M W Laschke; F Müller; P Rosenbaum; S Baum; E F Solomayer; U Ulrich
Journal:  Geburtshilfe Frauenheilkd       Date:  2014-08       Impact factor: 2.915

Review 2.  EMT, CTCs and CSCs in tumor relapse and drug-resistance.

Authors:  Abhisek Mitra; Lopa Mishra; Shulin Li
Journal:  Oncotarget       Date:  2015-05-10

3.  Contralateral ovarian endometrioma recurrence after unilateral salpingo-oophorectomy.

Authors:  Tokie Hidari; Tetsuya Hirata; Tomoko Arakawa; Kaori Koga; Kazuaki Neriishi; Shinya Fukuda; Akari Nakazawa; Natsuki Nagashima; Suke Ma; Hui Sun; Masashi Takamura; Miyuki Harada; Yasushi Hirota; Osamu Wada-Hiraike; Tomoyuki Fujii; Yutaka Osuga
Journal:  BMC Womens Health       Date:  2019-05-02       Impact factor: 2.809

4.  Epidemiology of Endometriosis in France: A Large, Nation-Wide Study Based on Hospital Discharge Data.

Authors:  Peter von Theobald; Jonathan Cottenet; Silvia Iacobelli; Catherine Quantin
Journal:  Biomed Res Int       Date:  2016-04-11       Impact factor: 3.411

5.  The recurrence rate of ovarian endometrioma in women aged 40-49 years and impact of hormonal treatment after conservative surgery.

Authors:  Nara Lee; Seunggi Min; Seyeon Won; Yeon Jean Cho; Miseon Kim; Mi Kyoung Kim; Yong Wook Jung; Bo Seong Yun; Seok Ju Seong; Mi-La Kim
Journal:  Sci Rep       Date:  2020-10-05       Impact factor: 4.379

6.  Expression of cellular adherent and invasive molecules in recurrent ovarian endometriosis.

Authors:  Tingting Wu; Rongyan Zhang; Qiaoying Jiang; Zhi Li; Ruijin Wu
Journal:  J Int Med Res       Date:  2020-11       Impact factor: 1.671

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.